Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- AstraZeneca to Boost Its Market Share to 4.3-4.5% by 2010: New President Kato
December 20, 2004
- PRESS SEMINAR
December 20, 2004
- MONITOR
December 20, 2004
- Most Widely Used Generics Are from Research-oriented Companies: JSGM Survey
December 20, 2004
- Dainippon, Sumitomo "Need to Consider Further M&A": Datamonitor
December 20, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 20, 2004
- ABeam Consulting Lists 5 Factors for Successful M&As
December 20, 2004
- Sanjiu Honsoudou Medical & Pharm. to Create Drug Wholesaler in China
December 20, 2004
- Eisai to Strengthen Business Infrastructure in China, India
December 20, 2004
- MEDICAL DEVICE NEWS IN BRIEF
December 20, 2004
- Results of Reevaluation Now Distributed in 4 Ways
December 20, 2004
- DIAGNOSTIC NEWS IN BRIEF
December 20, 2004
- BUSINESS NEWS IN BRIEF -1-
December 20, 2004
- BULLETIN
December 20, 2004
- Semi-annual Business Results
December 20, 2004
- NEW PRODUCTS
December 20, 2004
- Dainippon to Beef Up Sales of Prorenal
December 20, 2004
- New Company to Focus on OB/GYN, ENT, CV Areas: Teikoku Hormone, Grelan
December 20, 2004
- BUSINESS NEWS IN BRIEF -2-
December 20, 2004
- WEBSITE NEWS
December 20, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…